Roche signed a strategic collaboration and license deal with Manifold Bio to develop next‑generation brain shuttles, paying an upfront $55 million and structuring a partnership that could exceed $2 billion. The pact aims to advance transport technologies across the blood–brain barrier to deliver biologics and modalities for neurological diseases. Roche framed the deal as part of a broader push to improve CNS drug delivery at scale while Manifold will work on shuttles designed to carry diverse payloads. The collaboration follows Roche’s own late‑stage CNS programs and signals big pharma appetite for platform technologies that enable brain access. If Manifold’s shuttles translate, the agreement could unlock previously intractable CNS targets and reset valuation benchmarks for delivery platforms in neurology.